Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies
Abstract
:1. Introduction
2. Tau Protein
3. Tau Spreading Mechanisms
3.1. Which Are the Seeding Mechanisms?
3.2. Which Are the Releasing Mechanisms?
3.3. Which Tau Species Are Secreted?
3.4. Which Are the Uptaking Mechanisms?
3.5. How Does Propagation Occur?
4. Tau Spreading Implications for Dysfunctional Tauopathies
5. Conclusions
Conflicts of Interest
References
- Lee, V.M.; Goedert, M.; Trojanowski, J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24, 1121–1159. [Google Scholar] [CrossRef] [PubMed]
- Lewis, J.; Dickson, D.W. Propagation of tau pathology: Hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016, 131, 27–48. [Google Scholar] [CrossRef] [PubMed]
- Lee, V.M.; Trojanowski, J.Q. Neurodegenerative tauopathies: Human disease and transgenic mouse models. Neuron 1999, 24, 507–510. [Google Scholar] [CrossRef]
- Buée, L.; Delacourte, A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol. 1999, 9, 681–693. [Google Scholar] [CrossRef] [PubMed]
- Goedert, M.; Spillantini, M.G.; Potier, M.C.; Ulrich, J.; Crowther, R.A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain. EMBO J. 1989, 8, 393–399. [Google Scholar] [PubMed]
- Frost, B.; Jacks, R.L.; Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284, 12845–12852. [Google Scholar] [CrossRef] [PubMed]
- Clavaguera, F.; Bolmont, T.; Crowther, R.A.; Abramowski, D.; Frank, S.; Probst, A.; Fraser, G.; Stalder, A.K.; Beibel, M.; Staufenbiel, M.; et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell. Biol. 2009, 11, 909–913. [Google Scholar] [CrossRef] [PubMed]
- Walsh, D.M.; Selkoe, D.J. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 2016, 17, 251–260. [Google Scholar] [CrossRef] [PubMed]
- Weingarten, M.D.; Lockwood, A.H.; Hwo, S.Y.; Kirschner, M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA 1975, 72, 1858–1862. [Google Scholar] [CrossRef] [PubMed]
- Andreadis, A.; Brown, W.M.; Kosik, K.S. Structure and novel exons of the human tau gene. Biochemistry 1992, 31, 10626–10633. [Google Scholar] [CrossRef] [PubMed]
- Goedert, M.; Spillantini, M.G.; Jakes, R.; Rutherford, D.; Crowther, R.A. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 1989, 3, 519–526. [Google Scholar] [CrossRef]
- Lovestone, S.; Reynolds, C.H. The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 1997, 78, 309–324. [Google Scholar] [PubMed]
- Goedert, M.; Spillantini, M.G.; Hasegawa, M.; Jakes, R.; Crowther, R.A.; Klug, A. Molecular dissection of the neurofibrillary lesions of Alzheimer’s disease. Cold Spring Harb. Symp. Quant. Biol. 1996, 61, 565–573. [Google Scholar] [PubMed]
- Goedert, M.; Spillantini, M.G. Tau gene mutations and neurodegeneration. Biochem. Soc. Symp. 2001, 59–71. [Google Scholar] [CrossRef]
- Avila, J.; Lucas, J.J.; Perez, M.; Hernandez, F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 2004, 84, 361–384. [Google Scholar] [CrossRef] [PubMed]
- LoPresti, P.; Szuchet, S.; Papasozomenos, S.C.; Zinkowski, R.P.; Binder, L.I. Functional implications for the microtubule-associated protein tau: Localization in oligodendrocytes. Proc. Natl. Acad. Sci. USA 1995, 92, 10369–10373. [Google Scholar] [CrossRef] [PubMed]
- Dotti, C.G.; Banker, G.A.; Binder, L.I. The expression and distribution of the microtubule-associated proteins tau and microtubule-associated protein 2 in hippocampal neurons in the rat in situ and in cell culture. Neuroscience 1987, 23, 121–130. [Google Scholar] [CrossRef]
- Kaech, S.; Banker, G. Culturing hippocampal neurons. Nat. Protoc. 2006, 1, 2406–2415. [Google Scholar] [CrossRef] [PubMed]
- Ittner, L.M.; Ke, Y.D.; Delerue, F.; Bi, M.; Gladbach, A.; van Eersel, J.; Wölfing, H.; Chieng, B.C.; Christie, M.J.; Napier, I.A.; et al. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer’s disease mouse models. Cell 2010, 142, 387–397. [Google Scholar] [CrossRef] [PubMed]
- Brandt, R.; Léger, J.; Lee, G. Interaction of tau with the neural plasma membrane mediated by tau’s amino-terminal projection domain. J. Cell Biol. 1995, 131, 1327–1340. [Google Scholar] [CrossRef] [PubMed]
- Arrasate, M.; Pérez, M.; Avila, J. Tau dephosphorylation at tau-1 site correlates with its association to cell membrane. Neurochem. Res. 2000, 25, 43–50. [Google Scholar] [CrossRef] [PubMed]
- Sultan, A.; Nesslany, F.; Violet, M.; Bégard, S.; Loyens, A.; Talahari, S.; Mansuroglu, Z.; Marzin, D.; Sergeant, N.; Humez, S.; et al. Nuclear tau, a key player in neuronal DNA protection. J. Biol. Chem. 2011, 286, 4566–4575. [Google Scholar] [CrossRef] [PubMed]
- Trabzuni, D.; Wray, S.; Vandrovcova, J.; Ramasamy, A.; Walker, R.; Smith, C.; Luk, C.; Gibbs, J.R.; Dillman, A.; Hernandez, D.G.; et al. MAPT expression and splicing is differentially regulated by brain region: Relation to genotype and implication for tauopathies. Hum. Mol. Genet. 2012, 21, 4094–4103. [Google Scholar] [CrossRef] [PubMed]
- Boutajangout, A.; Boom, A.; Leroy, K.; Brion, J.P. Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer's disease. FEBS Lett. 2004, 576, 183–189. [Google Scholar] [CrossRef] [PubMed]
- Stamer, K.; Vogel, R.; Thies, E.; Mandelkow, E.; Mandelkow, E.M. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 2002, 156, 1051–1063. [Google Scholar] [CrossRef] [PubMed]
- Yuan, A.; Kumar, A.; Peterhoff, C.; Duff, K.; Nixon, R.A. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J. Neurosci. 2008, 28, 1682–1687. [Google Scholar] [CrossRef] [PubMed]
- Knops, J.; Kosik, K.S.; Lee, G.; Pardee, J.D.; Cohen-Gould, L.; McConlogue, L. Overexpression of tau in a nonneuronal cell induces long cellular processes. J. Cell Biol. 1991, 114, 725–733. [Google Scholar] [CrossRef] [PubMed]
- Frandemiche, M.L.; De Seranno, S.; Rush, T.; Borel, E.; Elie, A.; Arnal, I.; Lanté, F.; Buisson, A. Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-β oligomers. J. Neurosci. 2014, 34, 6084–6097. [Google Scholar] [CrossRef] [PubMed]
- Violet, M.; Delattre, L.; Tardivel, M.; Sultan, A.; Chauderlier, A.; Caillierez, R.; Talahari, S.; Nesslany, F.; Lefebvre, B.; Bonnefoy, E.; et al. A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front. Cell. Neurosci. 2014, 8, 84. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 2016, 17, 5–21. [Google Scholar] [CrossRef] [PubMed]
- Medina, M.; Hernández, F.; Avila, J. New features about tau function and dysfunction. Biomolecules 2016, 6, 21. [Google Scholar] [CrossRef] [PubMed]
- Hoover, B.R.; Reed, M.N.; Su, J.; Penrod, R.D.; Kotilinek, L.A.; Grant, M.K.; Pitstick, R.; Carlson, G.A.; Lanier, L.M.; Yuan, L.L.; et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68, 1067–1081. [Google Scholar] [CrossRef] [PubMed]
- Zempel, H.; Thies, E.; Mandelkow, E.; Mandelkow, E.M. Aβ oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 2010, 30, 11938–11950. [Google Scholar] [CrossRef] [PubMed]
- Grundke-Iqbal, I.; Iqbal, K.; Tung, Y.C.; Quinlan, M.; Wisniewski, H.M.; Binder, L.I. Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 1986, 83, 4913–4917. [Google Scholar] [CrossRef] [PubMed]
- Ittner, L.M.; Ke, Y.D.; Götz, J. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 2009, 284, 20909–20916. [Google Scholar] [CrossRef] [PubMed]
- Min, S.W.; Cho, S.H.; Zhou, Y.; Schroeder, S.; Haroutunian, V.; Seeley, W.W.; Huang, E.J.; Shen, Y.; Masliah, E.; Mukherjee, C.; et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010, 67, 953–966. [Google Scholar] [CrossRef] [PubMed]
- Cook, C.; Carlomagno, Y.; Gendron, T.F.; Dunmore, J.; Scheffel, K.; Stetler, C.; Davis, M.; Dickson, D.; Jarpe, M.; DeTure, M.; et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 2014, 23, 104–116. [Google Scholar] [CrossRef] [PubMed]
- Min, S.W.; Chen, X.; Tracy, T.E.; Li, Y.; Zhou, Y.; Wang, C.; Shirakawa, K.; Minami, S.S.; Defensor, E.; Mok, S.A.; et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 2015, 21, 1154–1162. [Google Scholar] [CrossRef] [PubMed]
- Martin, L.; Latypova, X.; Terro, F. Post-translational modifications of tau protein: Implications for Alzheimer's disease. Neurochem. Int. 2011, 58, 458–471. [Google Scholar] [CrossRef] [PubMed]
- Liu, F.; Zaidi, T.; Iqbal, K.; Grundke-Iqbal, I.; Gong, C.X. Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience 2002, 115, 829–837. [Google Scholar] [CrossRef]
- Watanabe, A.; Hong, W.K.; Dohmae, N.; Takio, K.; Morishima-Kawashima, M.; Ihara, Y. Molecular aging of tau: Disulfide-independent aggregation and non-enzymatic degradation in vitro and in vivo. J. Neurochem. 2004, 90, 1302–1311. [Google Scholar] [CrossRef] [PubMed]
- Yan, S.D.; Yan, S.F.; Chen, X.; Fu, J.; Chen, M.; Kuppusamy, P.; Smith, M.A.; Perry, G.; Godman, G.C.; Nawroth, P. Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat. Med. 1995, 1, 693–699. [Google Scholar] [CrossRef] [PubMed]
- Liu, F.; Iqbal, K.; Grundke-Iqbal, I.; Hart, G.W.; Gong, C.X. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2004, 101, 10804–10809. [Google Scholar] [CrossRef] [PubMed]
- Yuzwa, S.A.; Cheung, A.H.; Okon, M.; McIntosh, L.P.; Vocadlo, D.J. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J. Mol. Biol 2014, 426, 1736–1752. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.Z.; Grundke-Iqbal, I.; Iqbal, K. Glycosylation of microtubule-associated protein tau: An abnormal posttranslational modification in Alzheimer’s disease. Nat. Med. 1996, 2, 871–875. [Google Scholar] [CrossRef] [PubMed]
- Babu, J.R.; Geetha, T.; Wooten, M.W. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J. Neurochem. 2005, 94, 192–203. [Google Scholar] [CrossRef] [PubMed]
- Luo, H.B.; Xia, Y.Y.; Shu, X.J.; Liu, Z.C.; Feng, Y.; Liu, X.H.; Yu, G.; Yin, G.; Xiong, Y.S.; Zeng, K.; et al. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc. Natl. Acad. Sci. USA 2014, 111, 16586–16591. [Google Scholar] [CrossRef] [PubMed]
- Chai, X.; Dage, J.L.; Citron, M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis. 2012, 48, 356–366. [Google Scholar] [CrossRef] [PubMed]
- Karch, C.M.; Jeng, A.T.; Goate, A.M. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J. Biol. Chem. 2012, 287, 42751–42762. [Google Scholar] [CrossRef] [PubMed]
- Kim, W.; Lee, S.; Hall, G.F. Secretion of human tau fragments resembling CSF-tau in Alzheimer’s disease is modulated by the presence of the exon 2 insert. FEBS Lett. 2010, 584, 3085–3088. [Google Scholar] [CrossRef] [PubMed]
- Kim, W.; Lee, S.; Jung, C.; Ahmed, A.; Lee, G.; Hall, G.F. Interneuronal transfer of human tau between Lamprey central neurons in situ. J. Alzheimers Dis. 2010, 19, 647–664. [Google Scholar] [CrossRef] [PubMed]
- Plouffe, V.; Mohamed, N.V.; Rivest-McGraw, J.; Bertrand, J.; Lauzon, M.; Leclerc, N. Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLoS ONE 2012, 7, e36873. [Google Scholar] [CrossRef] [PubMed]
- Saman, S.; Kim, W.; Raya, M.; Visnick, Y.; Miro, S.; Jackson, B.; McKee, A.C.; Alvarez, V.E.; Lee, N.C.; Hall, G.F. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 2012, 287, 3842–3849. [Google Scholar] [CrossRef] [PubMed]
- Simón, D.; García-García, E.; Royo, F.; Falcón-Pérez, J.M.; Avila, J. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 2012, 586, 47–54. [Google Scholar] [CrossRef] [PubMed]
- Perez, M.; Cuadros, R.; Hernandez, F.; Avila, J. Secretion of full-length tau or tau fragments in a cell culture model. Neurosci. Lett. 2016, 634, 63–69. [Google Scholar] [CrossRef] [PubMed]
- Diaz-Hernandez, M.; Gomez-Ramos, A.; Rubio, A.; Gomez-Villafuertes, R.; Naranjo, J.R.; Miras-Portugal, M.T.; Avila, J. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J. Biol. Chem. 2010, 285, 32539–32548. [Google Scholar] [CrossRef] [PubMed]
- Gomez-Ramos, A.; Diaz-Hernandez, M.; Cuadros, R.; Hernandez, F.; Avila, J. Extracellular tau is toxic to neuronal cells. FEBS Lett. 2006, 580, 4842–4850. [Google Scholar] [CrossRef] [PubMed]
- Gomez-Ramos, A.; Diaz-Hernandez, M.; Rubio, A.; Miras-Portugal, M.T.; Avila, J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol. Cell. Neurosci. 2008, 37, 673–681. [Google Scholar] [CrossRef] [PubMed]
- Barten, D.M.; Fanara, P.; Andorfer, C.; Hoque, N.; Wong, P.Y.; Husted, K.H.; Cadelina, G.W.; Decarr, L.B.; Yang, L.; Liu, V.; et al. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J. Neurosci. 2012, 32, 7137–7145. [Google Scholar] [CrossRef] [PubMed]
- Yamada, K.; Cirrito, J.R.; Stewart, F.R.; Jiang, H.; Finn, M.B.; Holmes, B.B.; Binder, L.I.; Mandelkow, E.M.; Diamond, M.I.; Lee, V.M.; et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 2011, 31, 13110–13117. [Google Scholar] [CrossRef] [PubMed]
- Michel, C.H.; Kumar, S.; Pinotsi, D.; Tunnacliffe, A.; St George-Hyslop, P.; Mandelkow, E.; Mandelkow, E.M.; Kaminski, C.F.; Kaminski Schierle, G.S. Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology. J. Biol. Chem. 2014, 289, 956–967. [Google Scholar] [CrossRef] [PubMed]
- Falcon, B.; Cavallini, A.; Angers, R.; Glover, S.; Murray, T.K.; Barnham, L.; Jackson, S.; O’Neill, M.J.; Isaacs, A.M.; Hutton, M.L.; et al. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J. Biol. Chem. 2015, 290, 1049–1065. [Google Scholar] [CrossRef] [PubMed]
- Mirbaha, H.; Holmes, B.B.; Sanders, D.W.; Bieschke, J.; Diamond, M.I. Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J. Biol. Chem. 2015, 290, 14893–14903. [Google Scholar] [CrossRef] [PubMed]
- Wu, J.W.; Herman, M.; Liu, L.; Simoes, S.; Acker, C.M.; Figueroa, H.; Steinberg, J.I.; Margittai, M.; Kayed, R.; Zurzolo, C.; et al. Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 2013, 288, 1856–1870. [Google Scholar] [CrossRef] [PubMed]
- Fitzpatrick, A.W.P.; Falcon, B.; He, S.; Murzin, A.G.; Murshudov, G.; Garringer, H.J.; Crowther, R.A.; Ghetti, B.; Goedert, M.; Scheres, S.H.W. Cryo-EM structures of tau filaments from Alzheimer’s disease brain. Nature 2017, 547, 185–190. [Google Scholar] [CrossRef] [PubMed]
- Guo, J.L.; Lee, V.M. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 2011, 286, 15317–15331. [Google Scholar] [CrossRef] [PubMed]
- Meyer, V.; Dinkel, P.D.; Rickman Hager, E.; Margittai, M. Amplification of Tau fibrils from minute quantities of seeds. Biochemistry 2014, 53, 5804–5809. [Google Scholar] [CrossRef] [PubMed]
- Sanders, D.W.; Kaufman, S.K.; DeVos, S.L.; Sharma, A.M.; Mirbaha, H.; Li, A.; Barker, S.J.; Foley, A.C.; Thorpe, J.R.; Serpell, L.C.; et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014, 82, 1271–1288. [Google Scholar] [CrossRef] [PubMed]
- Dinkel, P.D.; Siddiqua, A.; Huynh, H.; Shah, M.; Margittai, M. Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. Biochemistry 2011, 50, 4330–4336. [Google Scholar] [CrossRef] [PubMed]
- Nonaka, T.; Watanabe, S.T.; Iwatsubo, T.; Hasegawa, M. Seeded aggregation and toxicity of α-synuclein and tau: Cellular models of neurodegenerative diseases. J. Biol. Chem. 2010, 285, 34885–34898. [Google Scholar] [CrossRef] [PubMed]
- Gerson, J.E.; Sengupta, U.; Lasagna-Reeves, C.A.; Guerrero-Muñoz, M.J.; Troncoso, J.; Kayed, R. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun. 2014, 2, 73. [Google Scholar] [CrossRef] [PubMed]
- Despres, C.; Byrne, C.; Qi, H.; Cantrelle, F.X.; Huvent, I.; Chambraud, B.; Baulieu, E.E.; Jacquot, Y.; Landrieu, I.; Lippens, G.; et al. Identification of the tau phosphorylation pattern that drives its aggregation. Proc. Natl. Acad. Sci. USA 2017, 114, 9080–9085. [Google Scholar] [CrossRef] [PubMed]
- Kaufman, S.K.; Sanders, D.W.; Thomas, T.L.; Ruchinskas, A.J.; Vaquer-Alicea, J.; Sharma, A.M.; Miller, T.M.; Diamond, M.I. Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron 2016, 92, 796–812. [Google Scholar] [CrossRef] [PubMed]
- Yamada, K. Extracellular Tau and Its Potential Role in the Propagation of Tau Pathology. Front. Neurosci. 2017, 11, 667. [Google Scholar] [CrossRef] [PubMed]
- Fuster-Matanzo, A.; Gessler, F.; Leonardi, T.; Iraci, N.; Pluchino, S. Acellular approaches for regenerative medicine: On the verge of clinical trials with extracellular membrane vesicles? Stem Cell. Res. Ther. 2015, 6, 227. [Google Scholar] [CrossRef] [PubMed]
- Fiandaca, M.S.; Kapogiannis, D.; Mapstone, M.; Boxer, A.; Eitan, E.; Schwartz, J.B.; Abner, E.L.; Petersen, R.C.; Federoff, H.J.; Miller, B.L.; et al. Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement. 2015, 11, 600–607. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Balaji, V.; Kaniyappan, S.; Krüger, L.; Irsen, S.; Tepper, K.; Chandupatla, R.; Maetzler, W.; Schneider, A.; Mandelkow, E.; et al. The release and trans-synaptic transmission of Tau via exosomes. Mol. Neurodegener. 2017, 12, 5. [Google Scholar] [CrossRef] [PubMed]
- Asai, H.; Ikezu, S.; Tsunoda, S.; Medalla, M.; Luebke, J.; Haydar, T.; Wolozin, B.; Butovsky, O.; Kügler, S.; Ikezu, T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 2015, 18, 1584–1593. [Google Scholar] [CrossRef] [PubMed]
- Théry, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9, 581–593. [Google Scholar] [CrossRef] [PubMed]
- Dujardin, S.; Bégard, S.; Caillierez, R.; Lachaud, C.; Delattre, L.; Carrier, S.; Loyens, A.; Galas, M.C.; Bousset, L.; Melki, R.; et al. Ectosomes: A new mechanism for non-exosomal secretion of tau protein. PLoS ONE 2014, 9, e100760. [Google Scholar] [CrossRef] [PubMed]
- Rustom, A.; Saffrich, R.; Markovic, I.; Walther, P.; Gerdes, H.H. Nanotubular highways for intercellular organelle transport. Science 2004, 303, 1007–1010. [Google Scholar] [CrossRef] [PubMed]
- Tardivel, M.; Bégard, S.; Bousset, L.; Dujardin, S.; Coens, A.; Melki, R.; Buée, L.; Colin, M. Tunneling nanotube TNT-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol. Commun. 2016, 4, 117. [Google Scholar] [CrossRef] [PubMed]
- Abounit, S.; Wu, J.W.; Duff, K.; Victoria, G.S.; Zurzolo, C. Tunneling nanotubes: A possible highway in the spreading of tau and other prion-like proteins in neurodegenerative diseases. Prion 2016, 10, 344–351. [Google Scholar] [CrossRef] [PubMed]
- Fontaine, S.N.; Zheng, D.; Sabbagh, J.J.; Martin, M.D.; Chaput, D.; Darling, A.; Trotter, J.H.; Stothert, A.R.; Nordhues, B.A.; Lussier, A.; et al. DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins. EMBO J. 2016, 35, 1537–1549. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez, L.; Mohamed, N.V.; Desjardins, A.; Lippé, R.; Fon, E.A.; Leclerc, N. Rab7A regulates tau secretion. J. Neurochem. 2017, 141, 592–605. [Google Scholar] [CrossRef] [PubMed]
- Mohamed, N.V.; Desjardins, A.; Leclerc, N. Tau secretion is correlated to an increase of Golgi dynamics. PLoS ONE 2017, 12, e0178288. [Google Scholar] [CrossRef] [PubMed]
- Pooler, A.M.; Phillips, E.C.; Lau, D.H.; Noble, W.; Hanger, D.P. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013, 14, 389–394. [Google Scholar] [CrossRef] [PubMed]
- Yamada, K.; Holth, J.K.; Liao, F.; Stewart, F.R.; Mahan, T.E.; Jiang, H.; Cirrito, J.R.; Patel, T.K.; Hochgräfe, K.; Mandelkow, E.M.; et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 2014, 211, 387–393. [Google Scholar] [CrossRef] [PubMed]
- Fá, M.; Puzzo, D.; Piacentini, R.; Staniszewski, A.; Zhang, H.; Baltrons, M.A.; Li Puma, D.D.; Chatterjee, I.; Li, J.; Saeed, F.; et al. Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Sci. Rep. 2016, 6, 19393. [Google Scholar] [CrossRef] [PubMed]
- Bright, J.; Hussain, S.; Dang, V.; Wright, S.; Cooper, B.; Byun, T.; Ramos, C.; Singh, A.; Parry, G.; Stagliano, N.; et al. Human secreted tau increases amyloid-β production. Neurobiol. Aging 2015, 36, 693–709. [Google Scholar] [CrossRef] [PubMed]
- Mohamed, N.V.; Plouffe, V.; Rémillard-Labrosse, G.; Planel, E.; Leclerc, N. Starvation and inhibition of lysosomal function increased tau secretion by primary cortical neurons. Sci. Rep. 2014, 4, 5715. [Google Scholar] [CrossRef] [PubMed]
- Holmes, B.B.; DeVos, S.L.; Kfoury, N.; Li, M.; Jacks, R.; Yanamandra, K.; Ouidja, M.O.; Brodsky, F.M.; Marasa, J.; Bagchi, D.P.; et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. USA 2013, 110, E3138–E3147. [Google Scholar] [CrossRef] [PubMed]
- Christianson, H.C.; Svensson, K.J.; van Kuppevelt, T.H.; Li, J.P.; Belting, M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc. Natl. Acad. Sci. USA 2013, 110, 17380–17385. [Google Scholar] [CrossRef] [PubMed]
- Mercer, J.; Helenius, A. Virus entry by macropinocytosis. Nat. Cell. Biol. 2009, 11, 510–520. [Google Scholar] [CrossRef] [PubMed]
- Gout, E.; Schoehn, G.; Fenel, D.; Lortat-Jacob, H.; Fender, P. The adenovirus type 3 dodecahedron’s RGD loop comprises an HSPG binding site that influences integrin binding. J. Biomed. Biotechnol. 2010, 2010, 541939. [Google Scholar] [CrossRef] [PubMed]
- Luo, W.; Liu, W.; Hu, X.; Hanna, M.; Caravaca, A.; Paul, S.M. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci. Rep. 2015, 5, 11161. [Google Scholar] [CrossRef] [PubMed]
- Medina, M.; Avila, J. The role of extracellular Tau in the spreading of neurofibrillary pathology. Front. Cell. Neurosci. 2014, 8, 113. [Google Scholar] [CrossRef] [PubMed]
- Clavaguera, F.; Hench, J.; Goedert, M.; Tolnay, M. Invited review: Prion-like transmission and spreading of tau pathology. Neuropathol. Appl. Neurobiol. 2015, 41, 47–58. [Google Scholar] [CrossRef] [PubMed]
- Guo, J.L.; Lee, V.M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 2014, 20, 130–138. [Google Scholar] [CrossRef] [PubMed]
- Iba, M.; Guo, J.L.; McBride, J.D.; Zhang, B.; Trojanowski, J.Q.; Lee, V.M. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J. Neurosci. 2013, 33, 1024–1037. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; Arteaga, J.; Cashion, D.K.; Chen, G.; Gangadharmath, U.; Gomez, L.F.; Kasi, D.; Lam, C.; Liang, Q.; Liu, C.; et al. A highly selective and specific PET tracer for imaging of tau pathologies. J. Alzheimers Dis. 2012, 31, 601–612. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Drouet, V.; Wu, J.W.; Witter, M.P.; Small, S.A.; Clelland, C.; Duff, K. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 2012, 7, e31302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brettschneider, J.; del Tredici, K.; Lee, V.M.; Trojanowski, J.Q. Spreading of pathology in neurodegenerative diseases: A focus on human studies. Nat. Rev. Neurosci. 2015, 16, 109–120. [Google Scholar] [CrossRef] [PubMed]
- Braak, H.; Braak, E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991, 1, 213–216. [Google Scholar] [CrossRef] [PubMed]
- Geddes, J.F.; Vowles, G.H.; Nicoll, J.A.; Révész, T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol. 1999, 98, 171–178. [Google Scholar] [CrossRef] [PubMed]
- McKee, A.C.; Stern, R.A.; Nowinski, C.J.; Stein, T.D.; Alvarez, V.E.; Daneshvar, D.H.; Lee, H.S.; Wojtowicz, S.M.; Hall, G.; Baugh, C.M.; et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013, 136, 43–64. [Google Scholar] [CrossRef] [PubMed]
- Jackson, W.S. Selective vulnerability to neurodegenerative disease: The curious case of Prion Protein. Dis. Model. Mech. 2014, 7, 21–29. [Google Scholar] [CrossRef] [PubMed]
- Clavaguera, F.; Akatsu, H.; Fraser, G.; Crowther, R.A.; Frank, S.; Hench, J.; Probst, A.; Winkler, D.T.; Reichwald, J.; Staufenbiel, M.; et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. USA 2013, 110, 9535–9540. [Google Scholar] [CrossRef] [PubMed]
- Venegas, C.; Kumar, S.; Franklin, B.S.; Dierkes, T.; Brinkschulte, R.; Tejera, D.; Saecker, A.V.; Stephanie, S.; Santarelli, F.; Kummer, M.P.; et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature 2017, 552, 355–361. [Google Scholar] [CrossRef] [PubMed]
- Johnson, S.M.; Connelly, S.; Fearns, C.; Powers, E.T.; Kelly, J.W. The transthyretin amyloidoses: From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J. Mol. Biol. 2012, 421, 185–203. [Google Scholar] [CrossRef] [PubMed]
- Wischik, C.M.; Staff, R.T.; Wischik, D.J.; Bentham, P.; Murray, A.D.; Storey, J.M.; Kook, K.A.; Harrington, C.R. Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer’s disease. J. Alzheimers Dis. 2015, 44, 705–720. [Google Scholar] [CrossRef] [PubMed]
- Hernández, F.; Gómez de Barreda, E.; Fuster-Matanzo, A.; Lucas, J.J.; Avila, J. GSK3: A possible link between β amyloid peptide and tau protein. Exp. Neurol. 2010, 223, 322–325. [Google Scholar] [CrossRef] [PubMed]
- Höglinger, G.U.; Huppertz, H.J.; Wagenpfeil, S.; Andrés, M.V.; Belloch, V.; León, T.; del Ser, T.; Investigators, T.M. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov. Disord. 2014, 29, 479–487. [Google Scholar] [CrossRef] [PubMed]
- Bae, E.J.; Lee, H.J.; Rockenstein, E.; Ho, D.H.; Park, E.B.; Yang, N.Y.; Desplats, P.; Masliah, E.; Lee, S.J. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 2012, 32, 13454–13469. [Google Scholar] [CrossRef] [PubMed]
- Aguzzi, A.; Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009, 64, 783–790. [Google Scholar] [CrossRef] [PubMed]
- Jucker, M.; Walker, L.C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013, 501, 45–51. [Google Scholar] [CrossRef] [PubMed]
- Kfoury, N.; Holmes, B.B.; Jiang, H.; Holtzman, D.M.; Diamond, M.I. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 2012, 287, 19440–19451. [Google Scholar] [CrossRef] [PubMed]
- Sigurdsson, E.M. Tau immunotherapy and imaging. Neurodegener. Dis. 2014, 13, 103–106. [Google Scholar] [CrossRef] [PubMed]
- Asuni, A.A.; Boutajangout, A.; Quartermain, D.; Sigurdsson, E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007, 27, 9115–9129. [Google Scholar] [CrossRef] [PubMed]
- Golde, T.E. Open questions for Alzheimer's disease immunotherapy. Alzheimers Res. Ther. 2014, 6, 3. [Google Scholar] [CrossRef] [PubMed]
- D’Abramo, C.; Acker, C.M.; Jimenez, H.T.; Davies, P. Tau passive immunotherapy in mutant P301L mice: Antibody affinity versus specificity. PLoS ONE 2013, 8, e62402. [Google Scholar] [CrossRef] [PubMed]
- Yanamandra, K.; Kfoury, N.; Jiang, H.; Mahan, T.E.; Ma, S.; Maloney, S.E.; Wozniak, D.F.; Diamond, M.I.; Holtzman, D.M. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013, 80, 402–414. [Google Scholar] [CrossRef] [PubMed]
- Reiber, H.; Felgenhauer, K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin. Chim. Acta 1987, 163, 319–328. [Google Scholar] [CrossRef]
- Leinenga, G.; Götz, J. Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model. Sci. Transl. Med. 2015, 7, 278ra33. [Google Scholar] [CrossRef] [PubMed]
- Ruzza, P.; Siligardi, G.; Hussain, R.; Marchiani, A.; Islami, M.; Bubacco, L.; Delogu, G.; Fabbri, D.; Dettori, M.A.; Sechi, M.; et al. Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro. ACS Chem. Neurosci. 2014, 5, 30–38. [Google Scholar] [CrossRef] [PubMed]
- Ruzza, P.; Vitale, R.M.; Hussain, R.; Biondi, B.; Amodeo, P.; Sechi, G.; Siligardi, G. Interactions of GFAP with ceftriaxone and phenytoin: SRCD and molecular docking and dynamic simulation. Biochim. Biophys. Acta 2016, 1860, 2239–2248. [Google Scholar] [CrossRef] [PubMed]
- Sechi, G.; Ceccherini, I.; Bachetti, T.; Deiana, G.A.; Sechi, E.; Balbi, P. Ceftriaxone for Alexander’s disease: A four-year follow-up. JIMD Rep. 2013, 9, 67–71. [Google Scholar] [CrossRef] [PubMed]
Tauopathies | Tau 3R/4R Ratio |
---|---|
Primary Tauopathies | |
Richardson’s syndrome | 1:2–4 |
Pick’s disease | 3:1 |
Frontotemporal dementia with parkinsonism-17 (FTDP-17) | 1:2 |
Postencephalic parkinsonism (PEP) | 1:1 |
Argylophilic grain disease | 1:2 |
Corticobasal degeneration | 1:2 |
Progressive supranuclear palsy (PSP) | 1:3–4 |
Parkinson-dementia complex (PDC Guam) | 1:1 |
Guadeloupean parkinsonism | 1:2 |
Secondary Tauopathies | |
Alzheimer’s Disease (AD) | 1:1 |
Creutzfeldt–Jakob disease | - |
Down’s syndrome | 1:1 |
Dementia pugilistica | 1:1 |
Familial British Dementia | - |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fuster-Matanzo, A.; Hernández, F.; Ávila, J. Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies. Int. J. Mol. Sci. 2018, 19, 645. https://doi.org/10.3390/ijms19030645
Fuster-Matanzo A, Hernández F, Ávila J. Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies. International Journal of Molecular Sciences. 2018; 19(3):645. https://doi.org/10.3390/ijms19030645
Chicago/Turabian StyleFuster-Matanzo, Almudena, Félix Hernández, and Jesús Ávila. 2018. "Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies" International Journal of Molecular Sciences 19, no. 3: 645. https://doi.org/10.3390/ijms19030645